A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del)

Modern Pathology

Volumn 26, Issue 7, 2013, Pages 1004-1012

  Huss, Sebastian ^a   Künstlinger, Helen ^a   Wardelmann, Eva ^a   Kleine, Michaela A ^a   Binot, Elke ^a   Merkelbach Bruse, Sabine ^a   Rüdiger, Thomas ^b   Mittler, Jens ^c   Hartmann, Wolfgang ^a   Büttner, Reinhard ^a   Schildhaus, Hans Ulrich ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

GIST; KIT exon 8; wild type

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; CELL PROLIFERATION; CLINICAL FEATURE; DISEASE REGISTRY; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MASTOCYTOSIS; PERITONEUM METASTASIS; PRIORITY JOURNAL; SMALL INTESTINE CANCER; SPINDLE CELL; ADOLESCENT; CHILD; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; AGED; AGED, 80 AND OVER; CHILD; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; YOUNG ADULT;

EID: 84879957303     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.47     Document Type: Article

References (47)

1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580. (Pubitemid 28067289)
2. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710. (Pubitemid 36159485)
3. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245-266.
4. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68. (Pubitemid 40023952)
5. Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477-489. (Pubitemid 43740149)
6. Wardelmann E, Losen I, Hans V, et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003;106:887-895. (Pubitemid 37071667)
7. Lasota J, Dansonka-Mieszkowska A, Sobin LH, et al. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004;84:874-883. (Pubitemid 38833247)
8. Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 2006;86:94-100. (Pubitemid 43250972)
9. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329-3337. (Pubitemid 37082727)
10. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23:5357-5364. (Pubitemid 46206989)
11. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-1103. (Pubitemid 44275331)
12. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-5367.
13. Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: Nanagement of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Compr Cancer Netw 2007;5(Suppl 2):S1-29; quiz S30.
14. Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5): V98-102.
15. Wardelmann E, Buttner R, Merkelbach-Bruse S, et al. Mutation analysis of gastrointestinal stromal tumors: Increasing significance for risk assessment and effective targeted therapy. Virchows Arch 2007;451: 743-749. (Pubitemid 47497944)
16. Daniels M, Lurkin I, Pauli R, et al. Spectrum of KIT/PDGFRA/BRAF mutations and phosphatidylinositol-3-kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett 2011;312: 43-54.
17. Tarn C, Rink L, Merkel E, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008;105:8387-8392. (Pubitemid 351904765)
18. Mussi C, Schildhaus HU, Gronchi A, et al. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Clin Cancer Res 2008;14:4550-4555.
19. Miettinen M, Fetsch JF, Sobin LH, et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: A clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006;30:90-96. (Pubitemid 43740214)
20. Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: A new syndrome distinct from the Carney triad. Am J Med Genet 2002;108:132-139.
21. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 2005;23:8812-8818. (Pubitemid 46211527)
22. Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA 2011;108:314-318.
23. Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with longterm follow-up and review of the literature. Am J Surg Pathol 2005;29:1373-1381. (Pubitemid 41368774)
24. Hartmann K, Wardelmann E, Ma Y, et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 2005;129:1042-1046. (Pubitemid 41242694)
25. Huss S, Wardelmann E, Goltz D, et al. Activating PDGFRA mutations in inflammatory fibroid polyps occur in exons 12, 14 and 18 and are associated with tumour localization. Histopathology 2012;61:59-68.
26. Merkelbach-Bruse S, Dietmaier W, Fuzesi L, et al. Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors. BMC Med Genet 2010;11:106.
27. Fassunke J, Blum MC, Schildhaus HU, et al. qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL. BMC Mol Biol 2010;11:100.
28. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83. (Pubitemid 44692418)
29. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348: 1201-1214. (Pubitemid 36359296)
30. Schildhaus HU, Cavlar T, Binot E, et al. Inflammatory fibroid polyps harbour mutations in the plateletderived growth factor receptor alpha (PDGFRA) gene. J Pathol 2008;216:176-182.
31. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004;22:4514-4522. (Pubitemid 41185118)
32. Beghini A, Larizza L, Cairoli R, et al. c-kit activating mutations and mast cell proliferation in human leukemia. Blood 1998;92:701-702. (Pubitemid 28323739)
33. Lanternier F, Cohen-Akenine A, Palmerini F, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS One 2008;3:e1906.
34. Lasota J, vel Dobosz AJ, Wasag B, et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest 2007;87: 1029-1041. (Pubitemid 47429185)
35. Shih LY, Liang DC, Huang CF, et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia 2008;22:303-307.
36. Molderings GJ, Meis K, Kolck UW, et al. Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. Immunogenetics 2010;62:721-727.
37. Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010;130:804-815.
38. Markova J, Trnkova Z, Michkova P, et al. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. Leuk Lymphoma 2009;50:1448-1460.
39. Goemans BF, Zwaan CM, Cloos J, et al. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657. Leuk Res 2010;34:1302-1307.
40. Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004;89: 920-925. (Pubitemid 39049899)
41. Fuster O, Barragan E, Bolufer P, et al. Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis. J Mol Diagn 2009;11:458-463.
42. Goemans BF, Zwaan CM, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric corebinding factor acute myeloid leukemia. Leukemia 2005;19:1536-1542. (Pubitemid 43090396)
43. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study. J Clin Oncol 2006;24:3904-3911. (Pubitemid 46630738)
44. Nanri T, Matsuno N, Kawakita T, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 2005;19:1361-1366. (Pubitemid 41136329)
45. Gari M, Goodeve A, Wilson G, et al. c-kit protooncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999;105:894-900. (Pubitemid 29309094)
46. Park SH, Chi HS, Min SK, et al. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 2011;35:1376-1383.
47. Ahmad F, D'Souza W, Mandava S, et al. Molecular analysis of WT1 and KIT mutations in patients from an Indian population with de novo acute myeloid leukemia: Determination of incidence, distribution patterns, and report of a novel KIT mutation. Leuk Lymphoma 2011;52:865-876.